-
1.发明授权Inhibition of excessive phospholipase A.sub.2 activity and/or production by non-antimicrobial tetracyclines 失效抑制过量磷脂酶A2活性和/或非抗微生物四环素生产
公开(公告)号：US5523297A
公开(公告)日：1996-06-04
申请号：US426899
申请日：1995-04-21
申请人： Waldemar Pruzanski , Lorne M. Golub , Peter Vadas , Robert A. Greenwald , Nangavarum S. Ramamurthy , Thomas F. McNamara
发明人： Waldemar Pruzanski , Lorne M. Golub , Peter Vadas , Robert A. Greenwald , Nangavarum S. Ramamurthy , Thomas F. McNamara
IPC分类号： A61K31/65
CPC分类号： A61K31/65
摘要： A method for treating mammals suffering from conditions associated with excess phospholipase A.sub.2 activity and/or production comprising administering to the mammal an effective amount of a non-antimicrobial tetracycline sufficient to inhibit excess phospholipase A.sub.2 activity and/or production is disclosed.
摘要翻译： 公开了一种治疗患有与过量磷脂酶A2活性和/或产物相关的病症的哺乳动物的方法，包括向哺乳动物施用有效量的足以抑制过量磷脂酶A2活性和/或产生的非抗微生物四环素。
-
2.发明授权Inhibition of excessive phospholipase A.sub.2 activity and/or production by non-antimicrobial tetracyclines 失效抑制过量磷脂酶A2活性和/或非抗微生物四环素生产
公开(公告)号：US6043231A
公开(公告)日：2000-03-28
申请号：US115158
申请日：1993-08-31
申请人： Waldemar Pruzanski , Lorne M. Golub , Peter Vadas , Robert A. Greenwald , Nangavarum S. Ramamurthy , Thomas F. McNamara
发明人： Waldemar Pruzanski , Lorne M. Golub , Peter Vadas , Robert A. Greenwald , Nangavarum S. Ramamurthy , Thomas F. McNamara
IPC分类号： A61K31/65
CPC分类号： A61K31/65 , Y10S514/825 , Y10S514/863 , Y10S514/895
摘要： A method for treating mammals suffering from conditions associated with excess phospholipase A.sub.2 activity and/or production comprising administering to the mammal an effective amount of a non-antimicrobial tetracycline sufficient to inhibit excess phospholipase A.sub.2 activity and/or production is disclosed. A pharmaceutical composition is also disclosed.
摘要翻译： 公开了一种治疗患有与过量磷脂酶A2活性和/或产物相关的病症的哺乳动物的方法，包括向哺乳动物施用有效量的足以抑制过量磷脂酶A2活性和/或产生的非抗微生物四环素。 还公开了药物组合物。
-
3.发明授权Antibodies that specifically bind to and inhibit human synovial phospholipase A.sub.2 type A 失效特异性结合并抑制人滑膜磷脂酶A2型A的抗体
公开(公告)号：US5552530A
公开(公告)日：1996-09-03
申请号：US283793
申请日：1994-08-01
摘要： Antibodies that specifically bind to and inhibit the enzymatic activity of synovial phospholipase A.sub.2 Type A are described. The antibodies may be used in assays for detection of synovial phospholipase A.sub.2 in biological samples.
摘要翻译： 描述了特异性结合并抑制滑膜磷脂酶A2型A的酶活性的抗体。 抗体可用于检测生物样品中滑膜磷脂酶A2的测定中。
-
公开(公告)号：US5019508A
公开(公告)日：1991-05-28
申请号：US215726
申请日：1988-07-06
摘要： Mammalian synovial phospholipase A.sub.2 (sPLA.sub.2) enzymes are provided, as well as DNA constructs encoding these enzymes, methods of producing the enzymes recombinantly, and antibodies thereto. Therapeutic methods employing anti-synovial phospholipase antibodies are also provided, in addition to diagnositc methods and other applications of sPLA.sub.2.
摘要翻译： 提供哺乳动物滑膜磷脂酶A2（sPLA2）酶，以及编码这些酶的DNA构建体，重组产生酶的方法及其抗体。 除了sPLA2的诊断方法和其他应用之外，还提供了使用抗滑膜磷脂酶抗体的治疗方法。
-
5.发明授权Use of platelet activating factor acetylhydrolase as biomarker for anaphylaxis 有权使用血小板激活因子乙酰水解酶作为过敏反应的生物标志物公开(公告)号：US08257697B2
公开(公告)日：2012-09-04
申请号：US12262949
申请日：2008-10-31
申请人： Peter Vadas
发明人： Peter Vadas
CPC分类号： G01N33/86 , A61K38/465 , C12Q1/56 , C12Y301/01047 , G01N2800/24
摘要： A method for determining a patient's susceptibility to anaphylaxis comprises assaying the activity of platelet activating factor acetylhydrolase (PAF-AH) activity and comparing the measured activity to a reference value, wherein the level of PAF-AH activity inversely correlates with the susceptibility to anaphylaxis. The method further comprises determining the severity of anaphylaxis by correlating the degree of reduced PAF-AH activity to the reference value. The method further comprises measuring IgE concentration and comparing the measured concentration to a reference concentration. The invention further provides a method for diagnosing anaphylaxis in a patient comprising measuring the serum concentration of platelet activating factor (PAF) and comparing the measured concentration to a reference value, wherein the concentration of PAF correlates directly with severity of anaphylaxis. The invention also provides a kit for performing the required assay or assays.
摘要翻译： 用于确定患者对过敏性易感性的方法包括测定血小板活化因子乙酰水解酶（PAF-AH）活性的活性并将测量的活性与参考值进行比较，其中PAF-AH活性水平与过敏反应的易感性成反比。 该方法还包括通过将降低的PAF-AH活性的程度与参考值相关联来确定过敏反应的严重程度。 该方法还包括测量IgE浓度并将测量的浓度与参考浓度进行比较。 本发明还提供了一种用于诊断患者过敏反应的方法，包括测量血小板活化因子（PAF）的血清浓度并将测量的浓度与参考值进行比较，其中PAF的浓度与过敏反应的严重程度直接相关。 本发明还提供了用于进行所需测定或测定的试剂盒。
-
6.发明申请USE OF PLATELET ACTIVATING FACTOR ACETYLHYDROLASE AS BIOMARKER FOR ANAPHYLAXIS 有权平板激活因子乙酰胆碱酯酶作为生物标记物的用途公开(公告)号：US20090110675A1
公开(公告)日：2009-04-30
申请号：US12262949
申请日：2008-10-31
申请人： Peter Vadas
发明人： Peter Vadas
CPC分类号： G01N33/86 , A61K38/465 , C12Q1/56 , C12Y301/01047 , G01N2800/24
摘要： A method for determining a patient's susceptibility to anaphylaxis comprises assaying the activity of platelet activating factor acetylhydrolase (PAF-AH) activity and comparing the measured activity to a reference value, wherein the level of PAF-AH activity inversely correlates with the susceptibility to anaphylaxis. The method further comprises determining the severity of anaphylaxis by correlating the degree of reduced PAF-AH activity to the reference value. The method further comprises measuring IgE concentration and comparing the measured concentration to a reference concentration. The invention further provides a method for diagnosing anaphylaxis in a patient comprising measuring the serum concentration of platelet activating factor (PAF) and comparing the measured concentration to a reference value, wherein the concentration of PAF correlates directly with severity of anaphylaxis. The invention also provides a kit for performing the required assay or assays.
摘要翻译： 用于确定患者对过敏性易感性的方法包括测定血小板活化因子乙酰水解酶（PAF-AH）活性的活性并将测量的活性与参考值进行比较，其中PAF-AH活性水平与过敏反应的易感性成反比。 该方法还包括通过将降低的PAF-AH活性的程度与参考值相关联来确定过敏反应的严重程度。 该方法还包括测量IgE浓度并将测量的浓度与参考浓度进行比较。 本发明还提供了一种用于诊断患者过敏反应的方法，包括测量血小板活化因子（PAF）的血清浓度并将测量的浓度与参考值进行比较，其中PAF的浓度与过敏反应的严重程度直接相关。 本发明还提供了用于进行所需测定或测定的试剂盒。
-
7.发明授权Use of platelet activating factor acetylhydrolase as a biomarker for anaphylaxis 有权使用血小板激活因子乙酰水解酶作为过敏反应的生物标志物公开(公告)号：US08562982B2
公开(公告)日：2013-10-22
申请号：US13602289
申请日：2012-09-03
申请人： Peter Vadas
发明人： Peter Vadas
CPC分类号： G01N33/86 , A61K38/465 , C12Q1/56 , C12Y301/01047 , G01N2800/24
摘要： The invention provides a use of platelet activating factor acetylhydrolase (PAF-AH) activity as a biomarker for severe or fatal anaphylaxis in a subject. The level of PAF-AH activity inversely correlates with the susceptibility to severe or fatal anaphylaxis. The use comprises assaying PAF-AH activity in a sample from the subject and comparing the measured activity to a reference value, wherein a lower level of measured PAF-AH activity relative to said reference level of PAF-AH activity indicates a presence of or susceptibility to severe or fatal anaphylaxis in the subject. A method for treating or preventing severe or fatal anaphylaxis in a subject is also provided. The method comprises increasing serum platelet activating factor acetylhydrolase (PAF-AH) concentration in the subject by administering to the subject, PAF-AH and/or a PAF receptor antagonist. A composition for treating severe or fatal anaphylaxis is also provided.
摘要翻译： 本发明提供血小板激活因子乙酰水解酶（PAF-AH）活性作为受试者中严重或致命性过敏反应的生物标志物的用途。 PAF-AH活性水平与严重或致命性过敏反应的易感性呈负相关。 该用途包括测定来自受试者的样品中的PAF-AH活性并将测量的活性与参考值进行比较，其中相对于所述参考水平的PAF-AH活性的较低水平的测量的PAF-AH活性指示存在或易感性 在主题中发生严重或致命的过敏反应。 还提供了治疗或预防受试者中严重或致命性过敏反应的方法。 该方法包括通过给予受试者PAF-AH和/或PAF受体拮抗剂来增加受试者的血小板活化因子乙酰水解酶（PAF-AH）浓度。 还提供了用于治疗严重或致命过敏反应的组合物。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.028 秒)
